Vitroscope raises $5M seed to keep living human tissue alive for drug testing

Vitroscope, a Trondheim startup that keeps living human tissue alive on a lab bench, has raised a $5M seed co-led by Cerberus Ventures and YZR Capital, plus a $2M non-dilutive grant from the Research Council of Norway.

Five million in equity, two million from the state

The round was announced on 3 November 2026, according to Tech.eu, and totals $7M. Cerberus Ventures and YZR Capital co-led the $5M seed. Arcas Ventures, Golden Egg Check, Devico Invest and the angels Carles Reina, Fàtima Godall and Oskari Pétas joined them. The other $2M is non-dilutive money from the Research Council of Norway. Vitroscope has now raised $8.8M in total.

The announced figures are in dollars. At the 3 November rate of 1.1177 dollars per euro, the seed is about €4.45M. The company says the money goes to the commercial rollout of its vitro.alive platform and to the validation of vitro.scale, its next system. Our Vitroscope profile holds the full record.

A bench that holds tissue steady for a week

Vitroscope was founded in 2019 and is based in Trondheim, Norway, according to its Startuplab listing. Its pitch starts from a simple gap: most lab biology gives a snapshot of tissue at one moment, and living tissue changes by the hour. “We started Vitroscope because living tissue cannot be reduced to a snapshot,” CEO and co-founder Carlo Kriesi said in the announcement.

vitro.alive is a benchtop platform with programmable perfusion, real-time control of oxygen, pH and temperature, and live cell imaging. It runs six experiments in parallel, fits standard inverted microscopes and accepts existing tissue models. With Instant Bio, Vitroscope kept vascularized human brain organoids under perfusion for seven days. The company holds several international patents.

vitro.scale is the bigger machine: 96 parallel experiments. Customer tests are planned for 2027 and the launch for 2028, so the seed has to carry a hardware company through two years before that system reaches a lab.

Sizing a market that starts small

So how big is the field around a bench like this? The closest segment with a published forecast is organ-on-chip: MarketsandMarkets valued it at $123.3M in 2024 and projects $631.1M by 2029, a 38.6% CAGR (report dated February 2024). Vitroscope’s perfused tissue culture sits next to that segment, and no reliable sizing exists for the exact niche. Read the 38.6% as a neighbor’s growth rate.

Two rounds on our own books give the amount a scale. ALLOX closed a €9.45M seed on 29 October, more than twice the size of Vitroscope’s. Samplix reported a €25M first close the same week, more than five times larger. A seed of this size is typical for a hardware team that needs instruments in customers’ hands before it can raise a real Series A.

Why a Norwegian grant sits beside two seed funds

The grant makes up two of the seven million dollars, close to 29% of the round. Instruments for drug discovery take years to validate, and a public funder that pays for the validation lets the private money go further. We are seeing the same mix across our fundraising data whenever a team sells hardware to pharma.

The investors frame the bet in their own words. “Biology isn’t static, but much of the way we study it still is,” said Chenny Zhang, Managing Director at Cerberus Ventures. YZR Capital’s Markus Feuerecker called the platform “physical AI infrastructure”. Imagine if every drug-screening dataset came from tissue that stayed alive for days instead of hours: the models trained on it would answer a different question.

That is the thing to watch. The 2027 customer tests of vitro.scale will show whether 96 parallel experiments on living tissue hold up outside Trondheim. Keep Vitroscope on your radar until then.